This article has Open Peer Review reports available.
Anti-HIV-1 activity, protease inhibition and safety profile of extracts prepared from Rhus parviflora
- Manoj Modi†1,
- Boskey Pancholi1,
- Shweta Kulshrestha2,
- Ajay Kumar Singh Rawat2,
- Swadesh Malhotra2Email author and
- Satish Kumar Gupta1Email author
© Modi et al.; licensee BioMed Central Ltd. 2013
Received: 20 October 2012
Accepted: 27 June 2013
Published: 4 July 2013
In the present study, extracts prepared from the leaves of Rhus parviflora Roxb. (Anacardiaceae) were evaluated for their anti-HIV activity, which have been traditionally used for the treatment of neurological disorders such as anxiety, insomnia and epilepsy.
Aqueous and 50% ethanolic extracts prepared from leaves of the plant were tested for their cytotoxicity and anti-HIV property using reporter gene based assays as well as human peripheral blood lymphocytes (PBLs). Further these extracts were evaluated for their ability to inhibit HIV-1 reverse transcriptase (RT) and protease activity. Safety profile of the extracts was determined on viability of Lactobacillus sp., secretion of pro-inflammatory cytokines by vaginal keratinocytes and transepithelial resistance.
Both aqueous (IC50 = 15 μg/ml) and 50% ethanolic (IC50 = 26 μg/ml) extracts prepared from leaves of R. parviflora showed anti-HIV activity in TZM-bl cells wherein the virus was treated with the extracts prior to infection. Further, both the extracts also inhibited virus load in HIV infected CEM-GFP cells and human PBLs. The anti-HIV activity is mediated through inhibition of HIV-1 protease activity. Both the extracts did not disturb the integrity of monolayer formed by intestinal epithelial Caco-2 cells. The extracts when tested up to 100 μg/ml did not significantly reduce the viability of L. plantarum, L. fermentum, L. rhamnosus and L. casei. The extracts (100 μg/ml) did not reveal any cytotoxic effect on vaginal keratinocytes (Vk2/E6E7). Levels of pro-inflammatory cytokines secreted by Vk2/E6E7 cells treated with both the plant extracts were within the non-inflammatory range.
The studies reported herein showed in vitro anti-HIV activity and preliminary safety profile of the extracts prepared from the leaves of R. parviflora.
Acquired Immunodeficiency Syndrome (AIDS), an immunological disorder characterized by abnormalities of immunoregulation and opportunistic infections, caused by the human immunodeficiency virus (HIV) is one of the major public health problems . Treatment of HIV infected patients with currently available highly active anti-retroviral (HAART) drugs though successful in reducing the burden of the disease but is associated with various side effects, including emergence of drug resistant HIV strains [2–6]. Hence, it is imperative to discover novel anti-HIV agents from natural sources that may have lesser side effects. Various studies have shown anti-HIV properties of the extracts prepared from variety of plants [7–9]. The plant extracts or purified phytochemicals may exhibit anti-HIV activity by inhibiting virus entry/fusion, HIV-1 reverse transcriptase (RT), protease or its integrase activity [10–13]. Further, to prevent sexual transmission of HIV, microbicides with anti-HIV properties have been proposed that can be applied topically before sexual act .
Rhus parviflora Roxb. (Anacardiaceae) is known as ‘Tintidika’ in Sanskrit language, widely distributed in Nepal, Northern India, Bhutan and Sri Lanka at the altitudinal range of 700–1100 m . It is recorded in Ayurvedic pharmacopoeia as having therapeutic uses for Vāta vikāra, the complications related to neurological disorders including anxiety, insomnia, epilepsy, and rheumatoid arthritis . In Nepal, fruits of R. parviflora are also used for human consumption and decoction of fruit or stem bark used to cure dysentery [17, 18]. Bark extract is applied externally on wounds and small twigs are used for cleaning teeth . In some tribal areas, infusions of leaves were given in cholera . Phytochemicals like gallic acid, some flavones viz., rutin, myricetin, quercetin, myricitrin, quercitrin, kampferol and some glycosides (isorhamnetin-3-α-L-arabinoside) have been isolated from the plant [16, 21].
The current study was undertaken to evaluate anti-HIV property of the aqueous and 50% ethanolic extracts prepared from leaves of R. parviflora using in vitro assays. Further, pre-clinical safety profile of these extracts with respect to viability of Lactobacillus sp., epithelial cell monolayer integrity and secretion of pro-inflammatory cytokines by vaginal keratinocytes has been studied.
Collection of plant material
Fresh leaves (1 kg) of the wild R. parviflora plant were collected in May 2008 from Khairna, Nainital, India (Accession Number-NBRH16) and specimen has been submitted to Herbarium of National Botanical Research Institute (NBRI), Lucknow, India. The plant material was collected and identified by Dr. A. K. S. Rawat, who is a taxonomist/botanist, Pharmacognosy Department, NBRI, Lucknow. The leaves were air and shade dried, grinded and strained through a mesh (size 30, mesh opening 0.5 mm).
Preparation of 50% ethanolic and aqueous extracts
To prepare 50% ethanolic extract, R. parviflora leaves powder (100 gm) was charged in a percolator, treated with ethanol: water (500 ml, 1:1 v/v) and left overnight at 25-30°C. The percolate (300 ml) was drained and the marc extracted thrice by cold percolation, each time with 500 ml of ethanol: water (1:1 v/v) and the combined percolate (1200 ml) was evaporated at 40-45°C under vacuum to concentrate the extract up to 80 ml. The concentrated 50% ethanolic extract was lyophilized at −20 to −40°C to afford 8-10% dried extract.
To prepare aqueous extract, R. parviflora leaves powder (100 gm) was treated with 500 ml of MilliQ water at 65-75°C for 6–8 h. The hot water extract was filtered through Whatman filter paper number 1. The marc was extracted thrice, each time with 500 ml of water at 60-75°C. The combined filtrate (1200 ml) was distilled at 45-50°C under vacuum to afford concentrated aqueous extract up to 70 ml. The extract was subsequently, lyophilized at −20 to −40°C to afford 9-11% dried extract. Both aqueous and 50% ethanolic extracts were characterized by High Performance Liquid Chromatography (HPLC), wherein 20 μl of the respective extract (1 mg/ml) was resolved by C18 column (Cap cell Pak C18, Phenomenex, CA, USA) using an isocratic acetonitrile and water supplemented with 10 mM formic acid (35:65; v/v), at a flow rate of 0.4 ml/min. The elution profile was monitored at 280 nm.
Cell maintenance and HIV
Anti-HIV assays were performed using TZM-bl [recombinant HeLa cell line expressing high levels of CD4, HIV-1 co-receptors CCR5 & CXCR4 with β-galactosidase and luciferase reporter genes under HIV-1 long terminal repeat (LTR) promoter] and CEM-GFP [a CD4+ T-lymphocytic reporter cell line expressing green fluorescent protein (GFP) under HIV-1 LTR promoter] reporter cells. TZM-bl cells were maintained in Dulbecco's modified Eagle’s medium (DMEM; Sigma-Aldrich Inc., St. Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS; Biological Industries, Kibbutz Beit Haemek, Israel) and antibiotic-antimycotic cocktail [Penicillin (100 units/ml), Streptomycin (100 μg/ml) and Amphotericin B (250 ng/ml); Pen-Strep-Ampho sol, Biological Industries] whereas, CEM-GFP cells in RPMI-1640 medium (Sigma-Aldrich Inc.) supplemented with 10% FBS, G418 (500 μg/ml; Gibco, Grand Island, NY, USA) and antibiotic-antimycotic cocktail as used for TZM-bl cells . Vk2/E6E7 cells (immortalized cell line derived from the normal human vaginal mucosa), a generous gift from Dr. Raina Fichorova (Brigham and Women’s Hospital, Boston, MA, USA), were cultured in Keratinocyte serum-free medium (ker-sfm) supplemented with bovine pituitary extract and epidermal growth factor (Gibco-Invitrogen, Carlsbad, CA, USA). Caco-2 cells (American Type Culture Collection, Manassas, VA, USA) were cultured in RPMI medium, supplemented with 10% FBS and previously used antibiotic-antimycotic cocktail. Saquinavir (Catalog Number 4658) was obtained from AIDS Research and Reference Reagent Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, USA.
HIV-1NL4.3 was prepared by transfection of HEK-293T cells with pNL4.3 plasmid (Catalog number 114; AIDS Research and Reference Reagent Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, USA) using CaPO4 method as described previously .
Cytotoxicity assay using MTT
The cytotoxicity of plant extracts on various cell lines was assessed by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Sigma-Aldrich Inc.] assay . In brief, cells were seeded (6 × 103 adherent cells/well; 5 × 104 suspension cells/well) in 96-well cell culture plates (Greiner Bio-One, GmbH, Frickenhausen, Germany) and grown overnight at 37°C in humidified atmosphere of 5% CO2. After 24 h, cells were treated with varying concentrations of the extracts ranging from 10–400 μg/ml, for the duration as used to determine the anti-HIV activity [TZM-bl cells - 48 h; CEM-GFP cells - 8 days with a change of medium on 5th day and human peripheral blood lymphocytes (PBLs) for 5 days]. Negative control included cells treated with solvent/medium. After incubation, cell viability was assessed by adding 20 μl MTT (5 mg/ml in 50 mM PBS) per well and incubated at 37°C for 3 h followed by addition of MTT solvent (100 μl/well; 20% SDS and 50% dimethyl formamide in 50 mM PBS) . The absorbance (OD) was read at 570 nm with reference filter at 690 nm. Experiments were performed in duplicates and percent viability was calculated by dividing the OD obtained in treatment group by OD of untreated cell control multiplied by hundred.
Anti-HIV activity using TZM-bl cells
In TZM-bl cells-based assay, HIV-1NL4.3 viral strain at a multiplicity of infection (MOI) of 0.05 was treated with varying concentrations (2–50 μg/ml) of extracts for 1 h at 37°C. Subsequently, HIV-1 pretreated with plant extracts was added to TZM-bl cells (4 × 104/well; seeded on the previous day in 24-well plate) and incubated for 4 h. Subsequently, cells were washed with cold 50 mM PBS, fresh culture medium with extracts added and further incubated for 48 h in humidified atmosphere of 5% CO2 at 37°C. Azidothymidine (AZT; Sigma-Aldrich Inc.) was used as positive reference control. After incubation, cells were washed twice with PBS and lysed with 1X lysis buffer (Promega Corporation, Madison, WI, USA). Supernatant was collected and luciferase activity was measured using white optiplate in the Fluorimeter (BMG Labtech GmbH, Offenberg, Germany). The results were expressed as percentage inhibition, calculated by taking the luminescence in experimental group divided by the luminescence in infected cells in absence of test extracts/AZT multiplied by hundred. Percent inhibition was calculated by subtracting the above value from hundred.
Inhibition of HIV infection using CEM-GFP cells-based assay
CEM-GFP cells (5 × 106) were infected with HIV-1NL4.3 virus at an MOI of 0.05 in presence of polybrene (2 μg/ml) for 4 h at 37°C with intermittent mixing as described previously . Post-infection, the cells were washed twice with serum free RPMI-1640 medium and were seeded (2.0 × 105/well) in a 24-well plate. Plant extracts at varying concentrations (1–50 μg/ml) were added to their respective wells. AZT was used as a positive control whereas solvents used to prepare extracts were used as negative controls. On 5th day, 0.4 ml of cell suspension was removed from each well, 1 ml fresh medium along with the extracts was added to the wells and plate was further incubated. On 8th day, 100 μl supernatant was collected for p24 analysis. For GFP estimation, cells were lysed with 150 μl of 1X Promega cell culture lysis buffer and lysate was centrifuged at 9000 × g for 10 min at 4°C. The supernatant (100 μl/well) was transferred to black optiplate and the absorbance was measured at an excitation wavelength of 485 nm and emission at 520 nm using Fluorimeter (FLUostar Optima, BMG Labtech, Germany). The results were expressed as percentage inhibition, calculated by taking the GFP fluorescence in experimental group divided by GFP fluorescence in infected cells in the absence of test extract/AZT multiplied by hundred. Percent inhibition was obtained by subtracting the above value from hundred.
Anti-HIV assay using human peripheral blood lymphocytes (PBLs)
All experiments using human blood cells were carried out under informed consent of the blood donors and following the clearance from the Institutional Bio-safety and Human Ethical Committee. Blood (5 ml) was taken from healthy HIV sero-negative donors and peripheral blood lymphocytes (PBLs) were isolated using Ficoll density gradient method. Cells (2 × 106 cells/ml) were stimulated for 3 days with 3 μg/ml phytohemagglutinin (PHA-P; Sigma-Aldrich Inc.) and after stimulation washed twice to remove PHA-P. Stimulated cells were infected by HIV-1NL4.3 at an MOI of 0.05, in presence of IL-2 (10 U/ml) for 4 h as described for CEM-GFP cells. Infected cells were washed twice with plain medium to remove the unbound virus and seeded in 96-well plate (5 × 104 cells/well), in 200 μl of RPMI medium supplemented with 10% FBS and 10 U/ml recombinant human IL-2. The extracts (20 μl/well) at varying concentrations, diluted in culture medium, were added in duplicate. Cells were cultured at 37°C, 5% CO2 and culture supernatant was collected on day 5 for p24 analysis.
The viral load in the supernatant (diluted 1:10 or 1:20) of CEM-GFP cells as well as human PBLs treated with plant extracts was measured using ELISA kits (SAIC-Frederick Inc., NCI-Frederick, USA; XpressBio, Life Science Products, MD, USA) for p24 estimation, following the instructions of the manufacturer. The non-specific inhibition of p24 binding to its antibody in ELISA in the presence of plant extracts was taken into account while calculating p24 concentration in the culture supernatants. Results were expressed as percent inhibition in virus load calculated by dividing the p24 concentration in the presence of plant extracts/AZT by p24 value observed in negative control, multiplied by hundred and the obtained value was subtracted from hundred.
HIV reverse transcriptase (RT) and protease assay
The inhibitory activity of plant extracts on HIV-1 RT was determined by commercial kit (Roche Applied Sciences, Mannheim, Germany) as per the manual’s instructions. In addition, effect of plant extracts on HIV-1 protease activity was also determined using kit (Anaspec, CA, USA) as per the manufacturer’s instructions.
Estimation for pro-inflammatory cytokines secreted by human cervico-vaginal keratinocytes
To study the toxic and inflammatory responses of the plant extracts, a human cervico-vaginal keratinocyte cell line (Vk2/E6E7) was used . Cells (6.0 × 103 cells/well) were seeded in 96-well culture plate and incubated in humidified atmosphere of 5% CO2 at 37°C for 24 h. After incubation, cells were treated with plant extracts (100 μg/ml) for 24 h and culture supernatant was collected for various cytokines quantiation using BDTM Cytometric Bead Array kit (BD FACSCanto Flow Cytometer; BD Biosciences Pharmigen, San Diego, CA, USA). The kit allows simultaneous quantification of interleukin (IL)-1β, IL-6, IL-8 and tumor necrosis factor (TNF). The cytokine bead assay was performed according to the manufacturer's specifications and data analysis was done using BD FACSDiva software. In addition, Vk2/E6E7 cells viability after 24 h treatment with test extracts was also determined by MTT assay as described above.
Transepithelial resistance (TER) measurement
Effect of the plant extracts on epithelial cells integrity (transepithelial resistance; TER) was measured using voltmeter. Caco-2 cells (5 × 105 cells/well) were grown in transwells and culture medium was dispensed in the basolateral compartment of each well. The cells were allowed to grow for 36–48 h in 5% CO2 at 37°C. Resistance was measured using Millicell–ERS voltmeter (EMD Millipore Corporation, Billerica, MA, USA) each day until resistance reached plateau. After formation of monolayer, extracts (50 μg/ml) was added in the culture medium and cells further incubated in humidified atmosphere of 5% CO2 at 37°C. Resistance was measured at intervals of 0.5, 1, 2, 4, 8 and 24 h (cells were incubated in 5% CO2 at 37°C in between each reading).
Effect of plant extracts on the viability of lactobacilli
Various lactobacilli strains such as Lactobacillus casie (MTCC 1423), L. fermentum (MTCC 903), L. plantarum (MTCC 4462) and L. rhamnosus (MTCC 1408) were obtained from Institute of Microbial Technology, Chandigarh, India and cultured in MRS broth (HiMedia, Mumbai, India). The cytotoxicity of plant extracts on lactobacilli was assessed by MTT assay as described previously [27, 28]. In brief, bacterial density was adjusted to an OD of 0.06 at a wavelength of 670 nm i.e. approximately 108 CFU/ml. Extracts were administered at concentrations ranging from 3.125-100 μg/ml into 96-well plates along with 30 μl of bacterial suspension. Final volume was made up to 100 μl using MRS broth. Negative control included cells treated with solvent/medium and Saquinavir, a known HIV-1 protease inhibitor was used as reference control. After incubation for 24 h at 37°C, 10 μl of MTT (5 mg/ml in 50 mM PBS; Sigma-Aldrich Inc.) was added to each well containing microbial inoculums and plant extracts. Plates were incubated for 3 h at 37°C, followed by centrifugation at 2500 g for 10 min. Supernatants were aspirated and 100 μl of acid-isopropanol (5 ml of 1 N HCl in 95 ml of isopropanol) was added to each well. Optical density was measured using micro plate spectrophotometer (ELX 800MS; BioTek Instrument Inc., Vermont, USA) at 540 nm using reference filter at 690 nm. Percent viability was calculated by dividing the absorbance of treated cells to untreated cells multiplied by hundred.
Analyses of concentration-response data were performed by the use of nonlinear curve-fitting program Prism (Graph Pad Software Inc., CA, USA) to determine CC50 and IC50 values. The results were average of 2–3 independent experiments. The statistical significance of the values obtained in different assays in presence of varying concentrations of the plant extract with respect to untreated group was calculated using one way ANOVA. A p-value of <0.05 was considered to be statistically significant.
Results and discussion
With the aim to discover new plants as a source for prevention of HIV infection, aqueous and 50% ethanolic extracts prepared from leaves of R. parviflora were evaluated for anti-HIV activity using reporter gene-based cells assays and human PBLs. The safety of the extracts with respect to the effect on epithelial cell integrity, adverse effect on the viability of lactobacilli as well as production of pro-inflammatory cytokines by vaginal keratinocytes was assessed. Analyses of the aqueous and 50% ethanolic extracts prepared from the leaves of R. parviflora by HPLC revealed these to be a complex mixture of phytochemicals (Additional file 1: Figure S1A, S1B). It is likely that the aqueous extract will have preponderance of polar compounds whereas 50% ethanolic extract will have higher concentration of non-polar compounds.
Aqueous and 50% ethanolic extracts from leaves of R. parviflora inhibit HIV-1 infection
In vitro cytotoxicity and anti-HIV activity of the extracts derived from leaves of R. parviflora using TZM-bl and CEM-GFP cells
50% Ethanolic extract
50% Ethanolic extract
Anti-HIV activity of the extracts from R. parviflora mediated by inhibiting HIV-1 protease activity
Since HIV-1 is a retrovirus, virally encoded enzyme reverse transcriptase (RT) that catalyzes the conversion of viral RNA to proviral DNA is an important target where the extract may act to inhibit HIV infection. For this, the RT activity was evaluated in presence and absence of extract using a kit (Roche Diagnostics). No inhibition in RT activity was observed in presence of both the extracts (50 μg/ml) as compared to Nevirapine (1 μM) used as a positive control with ~90% inhibition (data not shown). These results imply that anti-HIV activity of the leaves extract of R. parviflora is not mediated by inhibition of HIV-1 RT activity, rather the extract may act at different steps of HIV life cycle.
Extracts derived from R. parviflora has no adverse effect on trans-epithelial cells resistance and viability of lactobacilli
No significant increase in pro-inflammatory cytokines observed in human vaginal derived cells after treatment with extracts prepared from R. parviflora
Pro-inflammatory cytokines secretion by vaginal keratinocytes (Vk2/E6E7) after treatment with extracts prepared from R. parviflora leaves
Treatment with plant extract#
Level of pro-inflammatory cytokines (pg/ml)
2.0 ± 0.2
119.0 ± 9.1
288.0 ± 5.3
1.1 ± 0.6
50% Ethanolic extract
1.7 ± 0.0
164.4 ± 10.0
10.4 ± 1.0*
1.7 ± 0.3
1.6 ± 0.6
126.7 ± 9.4
241.5 ± 10.2
1.5 ± 0.4
In addition to its other traditional uses, the extracts prepared from R. parviflora have anti-HIV-1 property, which may be mediated through inhibition of HIV-1 protease activity. The extracts have no adverse effect on the growth of lactobacilli, epithelial monolayer integrity and subsequent to treatment with the extracts, pro-inflammatory cytokines levels are within the non-inflammatory range. These observations are encouraging and further safety and efficacy studies in vivo may be undertaken to explore potential of the extracts prepared from R. parviflora for prevention of HIV sexual transmission.
We would like to acknowledge the financial support from Department of Biotechnology, Government of India and Indian Council of Medical Research, Government of India. We would also like to thank NIH AIDS Research & Reference Reagent program, Division of AIDS, NIAID, NIH for providing us the molecular clone of HIV-1NL4.3.
- WHO, UNICEF and UNAIDS: UNAIDS/WHO AIDS epidemic update. 2011,http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/jc2216_worldaidsday_report_2011_en.pdf, November ,Google Scholar
- Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK: Panel on clinical practices for treatment of HIV. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med. 2002, 137: 381-433. 10.7326/0003-4819-137-5_Part_2-200209031-00001.View ArticlePubMedGoogle Scholar
- Hofman P, Nelson AM: The pathology induced by highly active antiretroviral therapy against human immunodeficiency virus: an update. Curr Med Chem. 2006, 13: 3121-3132. 10.2174/092986706778742891.View ArticlePubMedGoogle Scholar
- Este JA, Cihlar T: Current status and challenges of antiretroviral research and therapy. Antiviral Res. 2010, 85: 25-33. 10.1016/j.antiviral.2009.10.007.View ArticlePubMedGoogle Scholar
- Lange J: Triple combinations: present and future. J AIDS Hum Retrovirol. 1995, 10 (Suppl 1): 77-82.Google Scholar
- Agwu A, Lindsey JC, Ferguson K, Zhang H, Spector S, Rudy BJ, Ray SC, Douglas SD, Flynn PM, Persaud D, Pediatric AIDS Clinical Trials Group 381 Study Team: Analyses of HIV-1 drug-resistance profiles among infected adolescents experiencing delayed antiretroviral treatment switch after initial non-suppressive highly active antiretroviral therapy. AIDS Patient Care STDS. 2008, 22: 545-552. 10.1089/apc.2007.0200.View ArticlePubMedPubMed CentralGoogle Scholar
- Calabrese C, Berman SH, Babish JG, Ma X, Shinto L, Dorr M, Wells K, Wenner CA, Standish LJ: A phase I trial of andrographolide in HIV positive patients and normal volunteers. Phytother Res. 2000, 14: 333-338. 10.1002/1099-1573(200008)14:5<333::AID-PTR584>3.0.CO;2-D.View ArticlePubMedGoogle Scholar
- Hammar L, Hirsch I, Machado AA, De Mareuil J, Baillon JG, Bolmont C, Chermann JC: Lectin-mediated effects on HIV type 1 infection in vitro. AIDS Res Hum Retroviruses. 1995, 11: 87-95. 10.1089/aid.1995.11.87.View ArticlePubMedGoogle Scholar
- Lin YM, Anderson H, Flavin MT, Pai YH, Mata-Greenwood E, Pengsuparp T, Pezzuto JM, Schinazi RF, Hughes SH, Chen FC: In vitro anti-HIV activity of biflavonoids isolated from Rhus succedanea and Garcinia multiflora. J Nat Prod. 1997, 60: 884-888. 10.1021/np9700275.View ArticlePubMedGoogle Scholar
- Otake T, Mori H, Morimoto M, Ueba N, Sutardjo S, Kusumoto IT, Hattori M, Namba T: Screening of Indonesian plant extracts for anti-human immunodeficiency virus type I (HIV-I) activity. Phytother Res. 1995, 9: 6-10. 10.1002/ptr.2650090103.View ArticleGoogle Scholar
- Wang RR, Gu Q, Yang LM, Chen JJ, Li SY, Zheng YT: Anti HIV-1 activities of extracts from the medicinal plant Rhus Chinensis. J Ethnopharmacol. 2006, 105: 269-273. 10.1016/j.jep.2005.11.008.View ArticlePubMedGoogle Scholar
- Kim HJ, Woo ER, Shin CG, Park HK: A new flavonol glycoside gallate ester from Acer okamotoanum and its inhibitory activity against human immunodeficiency virus-1 (HIV-1) integrase. J Nat Prod. 1998, 61: 145-148. 10.1021/np970171q.View ArticlePubMedGoogle Scholar
- Ahn MJ, Kim CY, Lee JS, Kim TG, Kim SH, Lee CK, Lee BB, Shin GG, Huh H, Kim J: Inhibition of HIV-I integrase by galloyl glucose from Terminalia chebula and flavonol glycoside gallates from Euphorbia pekinensis. Planta Med. 2002, 68: 457-459. 10.1055/s-2002-32070.View ArticlePubMedGoogle Scholar
- Nutan , Gupta SK: Microbicides: a new hope for HIV prevention. Indian J Med Res. 2011, 134: 939-949. 10.4103/0971-5916.92639.View ArticlePubMed CentralGoogle Scholar
- Press JR, Shrestha KK, Sutton DA: Annotated checklist of the flowering plants of Nepal. 2000, London and Central Department of Botany, Kathmandu: The Natural History MuseumGoogle Scholar
- Shrestha S, Park JH, Lee DY, Cho JG, Cho S, Yang HJ, Yong HI, Yoon MS, Han DS, Baek NI: Rhus parviflora and its biflavonoid constituents, rhusflavone, induce sleep through the positive allosteric modulation of GABA (A)-benzodiazepine receptors. J Ethanopharmacol. 2012, 142: 213-220. 10.1016/j.jep.2012.04.047.View ArticleGoogle Scholar
- Bajracharya D: Nutritive values of Nepalese edible wild fruits. Z Lebensm Unters Forsch. 1980, 171: 363-366. 10.1007/BF01087135.View ArticlePubMedGoogle Scholar
- Bhattarai NK: Folk herbal medicines of Makawanpur district, Nepal. International J Pharmacog. 1991, 29: 284-295. 10.3109/13880209109082899.View ArticleGoogle Scholar
- Semwal DP, Saradhi PP, Kala CP, Sajwan BS: Medicinal plants used by local Vaidyas in Ukhimath block, Uttarakhand. Indian J Trad Knowledge. 2010, 9: 480-485.Google Scholar
- Kumar M, Sheikh MA, Bussmann RW: Ethno medicinal and ecological status of plants in Garhwal Himalaya. India J Ethnobiol Ethnomed. 2011, 7: 32-45. 10.1186/1746-4269-7-32.View ArticlePubMedGoogle Scholar
- Joseph GVR, Sathe MV: Pharmacognostic studies on the leaves of “Tintidika’ Rhus parviflora Roxb. J Drug Res Ayurveda Siddha. 2007, 28: 1-8.Google Scholar
- Gervaix A, West D, Leoni LM, Richman DD, Wong-Staal F, Corbeil J: A new reporter cell line to monitor HIV infection and drug susceptibility in vitro. Proc Natl Acad Sci USA. 1997, 94: 4653-4658. 10.1073/pnas.94.9.4653.View ArticlePubMedPubMed CentralGoogle Scholar
- Pear WS, Nolan GP, Scott ML, Baltimore D: Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA. 1993, 90: 8392-8396. 10.1073/pnas.90.18.8392.View ArticlePubMedPubMed CentralGoogle Scholar
- Mosmann T: Rapid colorimteric assay for cellular growth and survival; application to proliferation and cytotoxicity assays. J Immun Methods. 1983, 65: 55-63. 10.1016/0022-1759(83)90303-4.View ArticleGoogle Scholar
- Kumar M, Mitra D: Heat shock protein 40 is necessary for Human Immunodeficiency Virus-1 Nef-mediated enhancement of viral gene expression and replication. J Biol Chem. 2005, 280: 41-50.Google Scholar
- Fichorova RN, Rheinwald JG, Anderson DJ: Generation of papillomavirus-immortalized cell lines from normal human ectocervical, endocervical and vaginal epithelium that maintain expression of tissue specific differentiation proteins. Biol Reprod. 1997, 57: 847-855. 10.1095/biolreprod57.4.847.View ArticlePubMedGoogle Scholar
- Clancy CJ, Nguyen MH: Comparison of a photometric method with standardized methods of antifungal susceptibility testing of yeasts. J Clinical Microbiol. 1997, 35: 2878-2882.Google Scholar
- Malekinejad H, Tukmechi A, Ebrahimi H, Bazargani-Gilani B: One step forward to improve the latest method of antibacterial susceptibility testing of vitro-cultured bacteria: an implication for antibacterial efficacy of Enrofloxacine on Aeromonas hydrophila. World J Microbiol Biotech. 2011, 27: 147-151. 10.1007/s11274-010-0440-5.View ArticleGoogle Scholar
- Kratz JM, Andrighetti-Fröhner CR, Kolling DJ, Leal PC, Cirne-Santos CC, Yunes RA, Nunes RJ, Trybala E, Bergström T, Frugulhetti IC, Barardi CR, Simões CM: Anti-HSV-1 and anti-HIV-1 activity of Gallic acid and pentyl gallate. Mem Inst Oswaldo Cruz. 2008, 103: 437-442. 10.1590/S0074-02762008000500005.View ArticlePubMedGoogle Scholar
- Reutrakul V, Ningnuek N, Pohmakotr M, Yoosook C, Napaswad C, Kasisit J, Santisuk T, Tuchinda P: Anti HIV-1 flavonoid glycosides from Ochna integerrima. Planta Med. 2007, 73: 683-688. 10.1055/s-2007-981538.View ArticlePubMedGoogle Scholar
- Gali Y, Arien KK, Praet M, Van den Bergh R, Temmerman M, Delezay O, Vanham G: Development of an in vitro dual-chamber model of the female genital tract as a screening tool for epithelial toxicity. J Virol Methods. 2010, 165: 186-197. 10.1016/j.jviromet.2010.01.018.View ArticlePubMedGoogle Scholar
- Falagas ME, Betsi GI, Athanasiou S: Probiotics for the treatment of women with bacterial vaginosis. Clin Microbiol Infect. 2007, 13: 657-664. 10.1111/j.1469-0691.2007.01688.x.View ArticlePubMedGoogle Scholar
- Kempf C, Jentsch P, Barre-Sinoussi FB, Poirier B, Morgenthaler JJ, Morell A, Germann D: Inactivation of human immunodeficiency virus (HIV) by low pH and pepsin. J Acquir Immune Defic Syndr. 1991, 4: 828-830.PubMedGoogle Scholar
- Klebanoff SJ, Coombs RW: Virucidal effect of Lactobacillus acidophilus on human immunodeficiency virus type 1: possible role in heterosexual transmission. J Exp Med. 1991, 174: 289-292. 10.1084/jem.174.1.289.View ArticlePubMedGoogle Scholar
- Alberto MR, Farias ME, Manca De Nadra MC: Effect of gallic acid and catechin on Lactobacillus hilgardii 5w growth and metabolism of organic compounds. J Agric Food Chem. 2001, 49: 4359-4363. 10.1021/jf0101915.View ArticlePubMedGoogle Scholar
- Lee CH, Jenner AM, Low SC, Lee YK: Effect of tea phenolics and their aromatic fecal bacteria metabolites on intestinal micro biota. Res Microb. 2006, 157: 876-884. 10.1016/j.resmic.2006.07.004.View ArticleGoogle Scholar
- Fichorova RN, Zhou F, Ratnam V, Atanassova V, Jiang S, Strick N, Neurath AR: Anti-human immunodeficiency virus type 1 microbicides cellulose acetate 1,2-benzenedicarboxylate in a human in vitro model of vaginal inflammation. Antimicrob Agents Chemother. 2005, 49: 323-335. 10.1128/AAC.49.1.323-335.2005.View ArticlePubMedPubMed CentralGoogle Scholar
- Roddy RE, Zekeng L, Ryan KA, Tamoufe U, Weir SS, Wong EL: A controlled clinical trial of nonoxynol-9 film to reduce male-to-female transmission of sexually transmitted diseases. N Engl J Med. 1998, 339: 504-510. 10.1056/NEJM199808203390803.View ArticlePubMedGoogle Scholar
- Stafford MK, Ward H, Flanagan A, Rosenstein IJ, Taylor-Robinson D, Smith JR, Kitchen VS: Safety study of nonoxynol-9 as a vaginal microbicides: evidence of adverse effects. J Acquir Immune Defic Syndr Hum Retrovirol. 1998, 17: 327-331. 10.1097/00042560-199804010-00006.View ArticlePubMedGoogle Scholar
- Fichorova RN, Bajpai M, Chandra N, Hsiu JG, Spangler M, Ratnam V, Doncel GF: Interleukin (IL)-1, IL-6, and IL-8 predict mucosal toxicity of vaginal microbicidal contraceptives. Biol Reprod. 2004, 71: 761-769. 10.1095/biolreprod.104.029603.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6882/13/158/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.